Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer

Table 1

Clinical characteristics, response, and toxicity profile of patients.

Patient	Age/sex	Cancer and stage	PD-L1 expression. Other mutation	Previous lines of therapy	Best response	Length of therapy	Toxicity (grade)	Alive or dead
1	57/F	Lung SCC IV	<1%	Carbo Tax 2; AT - 3 doses	NA	NA		D (PD)
2	40/M	Lung ADC IV	NA	Carbo Tax 3 then Nivo 1	NA	NA		D(sepsis)
3	62/M	Lung SCC II	NA	Lobectomy then Cis Docetaxel 1 then Carbo Tax 1 then Nivo 10	SD	28 weeks. stopped due to pneumonitis	Pneumonitis (3)	Alive
4	45/M	Lung ADC IV	NA; BRAF V600	Carbo Alimta 4 then Alimta 4 then Nivo 10	PR	24 and ongoing	Colitis (2); Rash (1)	Alive
5	45/F	Lung ADC IV	<1%	Carbo Alimta 4 then Alimta 13 then Nivo 17 then Docetaxel	PR	34 weeks		Alive
6	56/M	Lung SCC IV	NA	Pembro 6 then Carbo Tax 2	SD	16 weeks		D(PD)
7	55/M	Lung ADC IV	20%; HER 2 Neu	Carbo Alimta 4 then Alimta 3 then Pembro 7 then Trastu + Pertuzumab	SD	22 weeks	Fatigue (1); Hypothyroidism	alive
8	60/M	Lung ADC IV	NA	Carbo Alimta 4 then Alimta 10 then Nivo 8	PR	16 and ongoing	Elevated TSH	alive
9	58/M	Lung mixed IV	NA	Cis Etopo x5 then Nivo 5	PD	NA		D(PD)
10	48/M	Lung ADC IV	90%; EGFR	Erlotinib 5 months then Pembro 2	PD	NA		D(PD)
11	40/F	Anal SCC IV	NA	Chemo RT hen CarboTax 5 then Nivo 1	NA	NA		D (PD)
12	54/M	Anal SCC IV	NA	Mitomycin Xeloda then Nivo 13	PD	26 weeks	Hypothyroidism	D(PD)
13	43/M	HCC III	NA	Regorafinib 24 then Nivo 12	SD	25 weeks	Fatigue (1)	D(PD)
14	44/M	HCC IV	NA	RFA, TACE hen Soafenib 3 months then Nivo 12	PR	25 and ongoing	Hyperglycemia, Hypothyroidism	Alive
15	59/M	RCC III	NA	Sorafenib then Sunitinib then Everolimus the Nivo 11 then Axitinib	SD	22 weeks	Elevated TSH	D(sepsis)
16	42/M	DLBCL IV	NA	RCHOP then RICE PBSCT then Nivo 10 then Rev Rtux 1	PD	22 weeks		D(PD)
17	56/M	Invasive basal	NA	Vsmodegib 6 then Nivo 10	PR	24 weeks and ongoing	Elevated TSH	alive

Abbreviations: SCC: squamous cell cancer. ADC: adenocarcinoma. RCC: renal cell cancer. HCC: hepatocellular cancer. DLBCL: diffuse large B cell lymphoma. Nivo: Nivolumab. Pembro: Pembrolizumab. AT: Atezolizumab. NA: not available. SD: stable disease. PR: partial response. PD: progressive disease. Carbo Tax: Carboplatin and Paclitaxel. Cis: Cisplatin. Trastu: Trastuzumab. Cis Etopo: Cisplatin Etoposide. RT: Radiation therapy. RFA: radiofrequency ablation. RCHOP: Rituximab, Cyclophosphamide, Adriamycin, Oncovin, Prednisone. RICE: Rituximab, Ifosfamide, Carboplatin, Etoposide. SCT: stem cell transplant. RR: Rituximab, Revlimid. D: Dead.